Showing 1 - 6 results of 6 for search 'M. S. Duh', query time: 0.03s Refine Results
  1. 1
    P840: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF PEGCETACOPLAN USING PRINCE TRIAL DATA VERSUS RAVULIZUMAB AND ECULIZUMAB IN COMPLEMENT-NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

    P840: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF PEGCETACOPLAN USING PRINCE TRIAL DATA VERSUS RAVULIZUMAB AND ECULIZUMAB IN COMPLEMENT-NAÏVE PATIENTS WITH PAROXYSMA... by R. Wong, J. Fishman, K. Wilson, M. Yeh, Z. Hakimi, C. Yee, L. Huynh, M. S. Duh

    Published 2022-06-01
    Get full text
    Article
  2. 2
    P1035: COUNTRY DIFFERENCES IN THE BURDEN OF PATIENTS WITH HYPEREOSINOPHILIC SYNDROME IN EUROPE

    P1035: COUNTRY DIFFERENCES IN THE BURDEN OF PATIENTS WITH HYPEREOSINOPHILIC SYNDROME IN EUROPE by J. Hwee, N. Kwon, R. Alfonso-Cristancho, L. Baylis, G. Requena, S. Du, A. Khanal, L. Huynh, M. S. Duh, R. W. Jakes

    Published 2022-06-01
    Get full text
    Article
  3. 3
    P1034: HEALTHCARE UTILIZATION OF PATIENTS WITH HYPEREOSINOPHILIC SYNDROME IN EUROPE

    P1034: HEALTHCARE UTILIZATION OF PATIENTS WITH HYPEREOSINOPHILIC SYNDROME IN EUROPE by J. Hwee, N. Kwon, R. Alfonso-Cristancho, L. Baylis, G. Requena, S. Du, A. Khanal, L. Huynh, M. S. Duh, R. W. Jakes

    Published 2022-06-01
    Get full text
    Article
  4. 4
    P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE

    P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE by A. Reiter, J. Gotlib, I. Álvarez-Twose, D. H. Radia, J. Luebke, P. J. Bobbili, A. Wang, C. Norregaard, S. Dimitrijević, E. Sullivan, M. Louie-Gao, J. Schwaab, I. A. Galinsky, C. Perkins, W. R. Sperr, P. Sriskandarajah, A. Chin, S. R. Sendhil, M. S. Duh, P. Valent, D. J. DeAngelo

    Published 2022-06-01
    Get full text
    Article
  5. 5
    P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY

    P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY by A. Reiter, J. Gotlib, I. Álvarez-Twose, D. H. Radia, J. Luebke, P. J. Bobbili, A. Wang, C. Norregaard, S. Dimitrijević, E. Sullivan, M. Louie-Gao, J. Schwaab, I. A. Galinsky, C. Perkins, W. R. Sperr, P. Sriskandarajah, A. Chin, S. R. Sendhil, M. S. Duh, P. Valent, D. J. DeAngelo

    Published 2022-06-01
    Get full text
    Article
  6. 6
    P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY

    P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY by A. Reiter, J. Gotlib, I. Álvarez-Twose, D. H. Radia, J. Luebke, P. J. Bobbili, A. Wang, C. Norregaard, S. Dimitrijević, E. Sullivan, M. Louie-Gao, J. Schwaab, I. A. Galinsky, C. Perkins, W. R. Sperr, P. Sriskandarajah, A. Chin, S. R. Sendhil, M. S. Duh, P. Valent, D. J. DeAngelo

    Published 2022-06-01
    Get full text
    Article

Search Tools: